Related Experiment Video
Updated: Jun 17, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
[Renin and the heart]
1Department of Cardiology, Medicine Faculty of Kocaeli University, Kocaeli, Turkey. dilekural@gmail.com
Insights
Direct renin inhibitor aliskiren reduces plasma renin activity, a cardiovascular risk factor, offering a novel approach to managing hypertension and cardiovascular diseases beyond blood pressure reduction.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- The renin-angiotensin system (RAS) is crucial in cardiovascular regulation.
- RAS inhibition lowers blood pressure but can increase plasma renin activity, posing residual cardiovascular risk.
- Existing treatments like ACE inhibitors and ARBs do not reduce plasma renin activity.
Purpose:
- To highlight aliskiren as a direct renin inhibitor.
- To differentiate aliskiren's mechanism from ACE inhibitors and ARBs.
- To discuss aliskiren's potential in cardiovascular disease management.
Summary:
- Aliskiren uniquely reduces plasma renin activity, an independent cardiovascular risk factor.
- Unlike ACE inhibitors and ARBs, aliskiren addresses the negative feedback issue in RAS blockade.
- Its efficacy and safety in hypertension are established, with ongoing research into its effects on cardiovascular mortality and morbidity.
Impact:
- Aliskiren offers a new therapeutic option for RAS blockade.
- It may mitigate residual cardiovascular risk associated with traditional RAS inhibitors.
- Further research is investigating its comprehensive impact on cardiovascular outcomes.
Abstract:
The inhibition of renin-angiotensin system (RAS) has an effect beyond reducing blood pressure in the treatment of cardiovascular diseases; it also reduces mortality and morbidity. Although the classic RAS blockage is effective, due to blockage of negative feedback inhibition, it increases plasma renin activity and as a result generates a residual cardiovascular risk. Different from ACE-i and ARB treatments, aliskiren, a direct renin inhibitor, is the only pharmacologic agent that noticeably reduces the plasma renin activity, an independent cardiovascular risk factor. This creates a new option in RAS blockage. The efficacy and safety of aliskiren in the treatment of hypertension has been well established. The effect of aliskiren on cardiovascular mortality and morbidity is being researched. At this point there are many experimental and clinical studies to answer questions on this subject.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Hormonal Regulation
Heart Failure II: Pathophysiology
Hypertension II: Pathophysiology

